The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Biliary cancer: Utility of next‐generation sequencing for clinical management
Open accessAbstract
BACKGROUND: Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit. METHODS: Hybrid capture–based comprehensive genomic profiling (CGP) was performed for 412 intrahepatic cholangiocarcinomas (IHCCAs), 57 extrahepatic cholangiocarcinomas (EHCCAs), and 85 gallbladder carcinomas (GBCAs). The mutational profile was correlated with the clinical outcome of standard and experimental therapies for 321 patients. Clinical variables, detected mutations, and administered therapies were correlated with overall survival (OS) in a Cox regression model. RESULTS: The most frequent genetic aberrations (GAs) observed were tumor protein 53 (TP53; 27%), cyclin‐dependent kinase inhibitor 2A/B (CDKN2A/B; 27%), KRAS (22%), AT‐rich interactive domain‐containing protein 1A (ARID1A; 18%), and isocitrate dehydrogenase 1 (IDH1; 16%) in IHCCA; KRAS (42%), TP53 (40%), CDKN2A/B (17%), and SMAD4 (21%) in EHCCA; and TP53 (59%), CDKN2A/B (19%), ARID1A (13%), and ERBB2 (16%) in GBCA. Fibroblast growth factor receptor (FGFR; 11%) and IDH mutations (20%) were mostly limited to IHCCA but appeared to be mutually exclusive. In the IHCCA group, TP53 and KRAS mutations were associated significantly with poor OS, whereas FGFR2 mutations were associated with improved OS (P = .001), a younger age at onset, and female sex. IDH1/2 mutations were not prognostic. In a multivariate model, the effects of TP53 and FGFR GAs remained significant (P < .05). Patients with FGFR GAs had superior OS with FGFR‐targeted therapy versus standard regimens (P = .006). Targeted therapy in IHCCA was associated with a numerical OS improvement (P = .07). CONCLUSIONS: This is the largest clinically annotated data set of BTC cases with CGP and indicates the potential of CGP for improving outcomes. CGP should be strongly considered in the management of BTC patients. Cancer 2016;122:3838–3847. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 4×
“The sequence analysis methods and validation of the CGP platform included extensive comparisons with orthogonal methodologies.(28) Base substitution detection was performed with a Bayesian methodology, which detected novel somatic mutations at a low mutant allele frequency (MAF) and with increased sensitivity for muta…”
MethodInfluentialRazumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
The Epidemiology of Cholangiocarcinoma
Shaib, Y., & El-Serag, H. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,132
de Groen, P. C., Gores, G. J., LaRusso, N. F., Gunderson, L. L., & Nagorney, D. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411807 · Cited by 955
Clinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
How to apply de Bruijn graphs to genome assembly
Compeau, P. E. C., Pevzner, P. A., & Tesler, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.2023 · Cited by 673
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · cited 1×
“IDH1 encodes the enzyme isocitrate dehydrogenase, which is involved in the citric acid cycle and other metabolic processes.(42) IDH1/2 mutations have been reported in 10% to 23% of cholangiocarcinoma cases and, as seen in the current study, have been found to be more prevalent in IHCCA (22%-28%) than EHCCA TABLE 2.”
BackgroundArai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
Eckel, F., & Schmid, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603648 · Cited by 464
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Self-citationMutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
Self-citationMutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Classification, Diagnosis, and Management of Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.09.009 · Cited by 312
Greulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., Zhang, X., Lee, S.-H., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 244
Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005) · The Journal of Pathology · doi:10.1002/path.1779 · Cited by 234
HER2/neu-directed therapy for biliary tract cancer
Javle, M., Churi, C., Kang, H. C., Shroff, R., Janku, F., Surapaneni, R., Zuo, M., Barrera, C., Alshamsi, H., Krishnan, S., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0155-z · Cited by 227
Self-citationGenetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 210
Systemic Therapy for Biliary Tract Cancers
Hezel, A. F., & Zhu, A. X. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0252 · Cited by 208
Diagnosis and management of cholangiocarcinoma
Sandhu, D. S., & Roberts, L. R. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0008-9 · Cited by 188
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition
Samartzis, E. P., Gutsche, K., Dedes, K. J., Fink, D. A., Stucki, M., & Imesch, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2092 · Cited by 148
Wernberg, J. A., & Lucarelli, D. D. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.01.009 · Cited by 146
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Voss, J. S., Holtegaard, L. M., Kerr, S. E., Fritcher, E. G. B., Roberts, L. R., Gores, G. J., Zhang, J., Highsmith, W. E., Halling, K. C., & Kipp, B. R. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.11.006 · Cited by 143
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 142
Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis
Charbel, H., & Al-Kawas, F. H. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0178-8 · Cited by 128
EGFR and HER2 expression in advanced biliary tract cancer
Harder, J., Waiz, O., Otto, F., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4511 · Cited by 124
Robertson, S., Hyder, O. N., Dodson, R. M., Nayar, S. K., Poling, J., Beierl, K. F., Eshleman, J. R., Lin, M., Pawlik, T. M., & Anders, R. A. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.07.026 · Cited by 108
Genetic profiling of intrahepatic cholangiocarcinoma
Andersen, J. B., & Thorgeirsson, S. S. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283523c7e · Cited by 104
Lee, H., Wang, K., Johnson, A., Jones, D., Ali, S. M., Elvin, J. A., Yelensky, R., Lipson, D., Miller, V. A., Stephens, P. J., et al. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203394 · Cited by 75
Self-citationJavle, M. M., Shroff, R. T., Zhu, A. X., Sadeghi, S., Choo, S., Borad, M. J., Lowery, M. A., El-Khoueiry, A. B., Macarulla, T. M., Philip, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.335 · Cited by 55
Self-citationLoaiza‐Bonilla, A. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.479 · Cited by 52
Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors
Augustine, M. M., & Fong, Y. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.10.001 · Cited by 49
Biliary tract carcinomas: From chemotherapy to targeted therapy
Marino, D., Leone, F., Cavalloni, G., Cagnazzo, C., & Aglietta, M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.06.006 · Cited by 44
Burris, H. A., Mellinghoff, I. K., Maher, E. A., Wen, P. Y., Beeram, M., Touat, M., Faris, J. E., Azad, N. S., Cloughesy, T. F., Gore, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-pl04-05 · Cited by 36
Targeted therapy for biliary tract cancers
Faris, J. E., & Zhu, A. X. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-011-0496-0 · Cited by 34
Advances in the management of biliary tract cancers.
Ciombor, K. K., & Goff, L. W. (2013) · PubMed · Cited by 26
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions
Andersen, J. B., & Thorgeirsson, S. S. (2013) · Hepatic Oncology · doi:10.2217/hep.13.4 · Cited by 21
Cited by
Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V., Borad, M. J., Bridgewater, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,116
Self-citationValle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Self-citationBrindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., Kemeny, N. E., O'Reilly, E. M., El-Dika, I., Jarnagin, W. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0078 · Cited by 582
Metadata
- Authors
- Javle, M., Bekaii‐Saab, T., Jain, A., Wang, Y., Kelley, R. K., Wang, K., Kang, H. C., Catenacci, D., Ali, S., Krishnan, S., Ahn, D., Bocobo, A. G., Zuo, M., Kaseb, A., Miller, V., Stephens, P. J., Meric‐Bernstam, F., Shroff, R., & Ross, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-09-13
- Volume
- 122
- Issue
- 24
- Pages
- 3838-3847
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2520639290
- Cited by
- 418
- References
- 46
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.